A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Completed · Phase 1
Conditions studied: Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, MSI-H Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Other Solid Tumors
In brief
This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.
Key facts
- Study ID
- NCT04440943
- Run by
- Celldex Therapeutics
- People needed
- 27
- Starts
- 2020-08-04
- Expected to finish
- 2023-04-06
- Last updated by the study team
- 2023-06-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Northside Hospital — Atlanta, Georgia, United States
- University of Chicago — Chicago, Illinois, United States
- Oncology Hematology West, PC dba Nebraska Cancer Specialists — Omaha, Nebraska, United States
- Duke Cancer Center — Durham, North Carolina, United States
- Providence Portland Medical Center — Portland, Oregon, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.